Related Experiment Video
Updated: Jul 8, 2025
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
14.3K
Stereotactic ablative radiotherapy for primary renal cell carcinoma
Daniel X Yang1, Young Suk Kwon1, Robert Timmerman1
1University of Texas Southwestern Medical Center, Dallas, TX, United States.
Clinical and Translational Radiation Oncology
|December 11, 2023
Summary
Stereotactic ablative radiotherapy (SAbR) offers a non-invasive treatment for primary renal cell carcinoma (RCC), achieving high local control with low toxicity. Emerging research explores SAbR
Area of Science:
- Oncology
- Radiation Oncology
- Nephrology
Background:
- Stereotactic ablative radiotherapy (SAbR) is an emerging non-invasive treatment for primary renal cell carcinoma (RCC).
- SAbR is particularly suitable for patients unsuitable for surgery.
- Previous beliefs about renal cell carcinoma radio-resistance are being challenged by SAbR efficacy.
Purpose of the Study:
- To review the evidence supporting SAbR for primary renal cell carcinoma.
- To discuss ongoing clinical investigations of SAbR in metastatic disease.
- To highlight SAbR's potential role in multidisciplinary RCC management.
Main Methods:
- Review of preclinical data, dose escalation studies, and prospective trials.
- Analysis of outcomes from multi-institutional registries.
- Examination of clinical investigations combining SAbR with systemic therapies for metastatic RCC.
Main Results:
- SAbR demonstrates high local control rates for primary RCC.
- SAbR exhibits a favorable toxicity profile.
- Evidence suggests potential immunomodulatory effects of SAbR.
Conclusions:
- SAbR is a promising treatment option for primary renal cell carcinoma.
- SAbR is increasingly integrated into multidisciplinary RCC management.
- Further research is investigating SAbR combinations for metastatic disease.
